

Gibson Dunn Advising Merck on \$9.2 Billion Acquisition of Cidara Therapeutics

Firm News | November 14, 2025

Gibson Dunn is advising Merck on its \$9.2 billion acquisition of Cidara Therapeutics, Inc., a biotechnology company developing drug-Fc conjugate (DFC) therapeutics.

Our corporate team is led by partner Saeed Muzumdar and includes partner Sebastian Fain and associates Tracey Tomlinson and Kira Dennis. Partner Pamela Lawrence Endreny is advising on tax aspects. Partner Michael Collins is advising on benefits. Partner Karen Spindler is advising on life sciences aspects. Partner Meghan Hungate and associates Jacqueline Malzone and Mona Mosavi are advising on IP aspects. Partners Steve Weissman and Bradley Smith and associate Caroline Black are advising on antitrust aspects. Partner Katlin McKelvie is advising on FDA-related aspects.

Related People

[Saeed Muzumdar](#)

[Sebastian L. Fain](#)

[Tracey Tomlinson](#)

[Kira Dennis](#)

[Pamela Lawrence Endreny](#)

[Michael Collins](#)

[Karen A. Spindler](#)

[Meghan M. Hungate](#)

[Jacqueline E. Malzone](#)

[Mona Mosavi](#)

[Stephen Weissman](#)

[Bradley P. Smith](#)

[Caroline M.L. Black](#)

[Katlin McKelvie](#)

Related Capabilities

[Life Sciences](#)

[Mergers and Acquisitions](#)